Abstract: A composite resin composition and a molded product for a vehicle interior using the composite resin composition are disclosed. The molded product is manufactured from the composite resin composition at low cost in an eco-friendly manner by removing a painting or fiber wrapping operation. The composite resin effectively improves surface quality of the molded product for a vehicle interior.

Abstract: The present invention relates to an apparatus and method for encoding and decoding an image by skip encoding. The image-encoding method by skip encoding, which performs intra-prediction, comprises: performing a filtering operation on the signal which is reconstructed prior to an encoding object signal in an encoding object image; using the filtered reconstructed signal to generate a prediction signal for the encoding object signal; setting the generated prediction signal as a reconstruction signal for the encoding object signal; and not encoding the residual signal which can be generated on the basis of the difference between the encoding object signal and the prediction signal, thereby performing skip encoding on the encoding object signal.

Abstract: The present invention relates to a container cap and, more specifically, to: a container cap which is coupled to the mouth of a container in which contents are contained; and a container having same coupled thereto. The present invention provides a container cap comprising: a body part coupled to the mouth of a container in which contents are contained, and having an opening at the top thereof; a cover part coupled to the body part so as to open and close the top opening of the body part; and a separation part integrally connected to a first member, which is one of the body part and the cover part, by a first connection part, and integrally but detachably connected to a second member, which is the other of the body part and the cover part, by a second connection part, wherein the second connection part is detached by a user's manipulation so as to allow the cover part to be separated from the body part.

Abstract: The present invention relates to a vacuum drying method for botulinum toxin, and specifically to a vacuum drying method for botulinum toxin, comprising the steps of: a) first drying of a solution containing botulinum toxin at a temperature of 5° C. to 30° C. under a pressure of 0.01 to 2 mmHg; b) a second drying of the first-dried product obtained in step a) at a temperature of 5° C. to 20° C. under a pressure of 0.01 to 1 mmHg; and c) final drying of the second-dried product obtained in step b) at a temperature of 5° C. to 30° C. under a pressure of 0.01 to 0.5 mmHg. The present invention can advantageously improve yield, stability and manufacturing efficiency, compared to conventional methods for vacuum drying botulinum toxin by freeze-drying.

Abstract: The present invention relates to a container lid, and a container assembly having same coupled thereto and, more specifically, to a container lid coupled to a container inlet through which contents are received, and a container assembly having the container lid coupled thereto. Disclosed is a container assembly comprising: a container for receiving contents; a container lid coupled to the container inlet; and a sealing member having a bottom surface attached to an upper end of the container inlet of the container, and coupled to the container lid, wherein, when the container lid is separated from the container by means of rotation, adhesiveness between the sealing member and the container lid is greater than adhesiveness between the container inlet and the sealing member such that the sealing member is separated from the container inlet.

Abstract: Disclosed is a container stopper (100) coupled to a container inlet (12) of a container (10) in which content is held, the container stopper comprising: a stopper body (110) that is coupled to the container inlet (12) and has, on the upper side thereof, an auxiliary space (S1) in which auxiliary content (42) having a granular structure is held; and an upper cover (120) that is coupled to the stopper body (110), forms the auxiliary space (S1) together with the stopper body (110), and covers the auxiliary space (S1).

Abstract: A compound of the present invention, which is a tricyclic derivative represented by chemical formula 1 or a pharmaceutically acceptable salt thereof, has an excellent inhibitory effect on serotonin activity and a pharmaceutical composition comprising same can be thus advantageously used for preventing or treating a metabolic disease associated with serotonin activation, etc.

Abstract: A container cap which is combined with a container containing a beverage or the like, and a container combined with the container cap. The container cap is combined with a container inlet of a container body. A plurality of close contact portions in contact with the container inlet are formed, and the close contact portions form a closed curve enclosing the container inlet so as to block inflow of external air from the outside into the container body.

Abstract: The present invention relates to a botulinum toxin preparation method capable of obtaining botulinum toxin in a high yield through a simplified process that does not include animal-derived ingredients. The botulinum toxin preparation method according to the present invention does not use any animal ingredients in the overall process, including the culturing of a Clostridium botulinum strain, thereby providing excellent safety, omits a separate nucleic acid removal step using an additive treatment when compared with a conventional isolation process, and performs processing using only ion exchange chromatography, and it was confirmed that the botulinum toxin can be isolated at a remarkably improved yield through a simplified process by using the same buffer and only adjusting the concentration and pH of the buffer, and thus the present invention is a very economical and efficient isolation method so that the botulinum toxin isolated thereby is expected to be effectively used in beauty and medicine fields.

Abstract: The present invention relates to a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition including same, wherein the novel tryptophan hydroxylase inhibitor has an excellent inhibitory effect on TPH1, and thus can be usefully used for the prevention or treatment of disorders, such as metabolic disorders, cancer, digestive or cardiovascular system disorders, related to TPH1 activity. In particular, the novel tryptophan hydroxylase inhibitor has an excellent treatment effect on inflammatory bowel disorders, and thus can be usefully used for the treatment of inflammatory bowel disorder.

Abstract: The present invention relates to a novel phenylsulfonyl oxazole derivative and a use thereof and specifically, to a compound represented by Chemical Formula 1 in the present specification or a pharmaceutically acceptable salt thereof, and to a use thereof for prevention, treatment, or improvement of neurodegenerative disease.

Abstract: The present invention relates to a novel tryptophan hydroxylase inhibitor and a pharmaceutical composition including same, wherein the novel tryptophan hydroxylase inhibitor has an excellent inhibitory effect on TPH1, and thus can be usefully used for the prevention or treatment of disorders, such as metabolic disorders, cancer, digestive or cardiovascular system disorders, related to TPH1 activity. In particular, the novel tryptophan hydroxylase inhibitor has an excellent treatment effect on inflammatory bowel disorders, and thus can be usefully used for the treatment of inflammatory bowel disorder.

Abstract: The present invention relates to a novel phenylsulfonyl oxazole derivative and a use thereof and specifically, to a compound represented by Chemical Formula 1 in the present specification or a pharmaceutically acceptable salt thereof, and to a use thereof for prevention, treatment, or improvement of neurodegenerative disease.

Abstract: Provided are a compound of chemical formula 1 or 2 and a use thereof. The compound can be advantageously used in the prevention or treatment of metabolic diseases including type 2 diabetes, insulin resistance, or obesity, on the basis of a mechanism of autophagy activation through the promotion of lysosome production.

Abstract: Provided are a compound of chemical formula 1 or 2 and a use thereof. The compound can be advantageously used in the prevention or treatment of metabolic diseases including type 2 diabetes, insulin resistance, or obesity, on the basis of a mechanism of autophagy activation through the promotion of lysosome production.

Abstract: In a finished product used by coupling a 2-piece bottle cap formed of a cover and a body to the opening of a bottle, everything relating to the bottle cap having the body or the cover of various structures in which a desired number of the contents stored in the inner space of the bottle is left remained in a keeping groove when the cover coupled by screw threads to the body is opened after the finished product is turned 90-180 degrees upside down from an upright standing position and then rotated to the upright position, is disclosed.

Abstract: The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.

Abstract: The present invention relates to a beta-alanine derivative, pharmaceutically acceptable salts thereof, and a pharmaceutical composition including the same as an active ingredient. The novel beta-alanine derivative and pharmaceutically acceptable salts thereof according to the present invention may effectively inhibit the activity of DGAT1, which is an enzyme serving as a catalyst in the final step of the synthesis of neutral lipids, to thereby be effectively used as a pharmaceutical composition for preventing or treating various lipid metabolism-related disorders selected from the group consisting of obesity, dyslipidemia, fatty liver, insulin resistance syndrome, and hepatitis.

Abstract: Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1), and is useful in the treatment of various diseases that are mediated by 11?-HSD1.

Abstract: Provided is a sulfamide derivative having an adamantyl group represented by the following Formula 1, or a pharmaceutically acceptable salt thereof. The sulfamide derivative suppresses the activity of 11?-hydroxysteroid dehydrogenase type 1 (11?-HSD1), and is useful in the treatment of various diseases that are mediated by 11?-HSD1.